AR069636A1 - TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS. - Google Patents
TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS.Info
- Publication number
- AR069636A1 AR069636A1 ARP080105333A ARP080105333A AR069636A1 AR 069636 A1 AR069636 A1 AR 069636A1 AR P080105333 A ARP080105333 A AR P080105333A AR P080105333 A ARP080105333 A AR P080105333A AR 069636 A1 AR069636 A1 AR 069636A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- amino
- aminocarbonyl
- carbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Reivindicacion 1: Compuesto de la formula (1) en la que u representa N, V representa CR12, w representa N, A representa CR15; o u representa N, v representa N, w representa CR16, A representa N, donde R12 representa hidrogeno, hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, trifluorometilo, trifluorometoxi, ciano, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino, alquil C1-4-sulfonilamino, heterociclilcarbonilo de 5 o 6 miembros, -CH2R13 o -CH2CH2R14, donde heterociclilcarbonilo está sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde alcoxi, alquilamino, alquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo, alquilcarbonilamino y alquilsulfonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, alquil C1-4-carbonilamino, heterociclilo de 5 o 6 miembros y fenilo, donde fenilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde R13 representa hidroxilo, amino, ciano, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino o heterociclilo de 5 o 6 miembros, donde alcoxi, alquilamino, alcoxicarbonilo, alquilaminocarbonilo y alquilcarbonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde R14 representa hidroxilo, amino, ciano, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino o heterociclilo de 5 o 6 miembros, donde alcoxi, alquilamino, alcoxicarbonilo, alquilaminocarbonilo y alquilcarbonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 2 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, R15 representa hidrogeno, halogeno, ciano, trifluorometilo, alquilo C1-3, metoxi, metiltio o ciclopropilo, R16 representa hidrogeno o metilo; representa un resto del grupo de formulas (2) en las que * es el punto de union al heterociclo, n representa el numero 0 o 1; X representa NR10, S u O, donde R10 representa hidrogeno, alquilo C1-3 o ciclopropilo, Y representa NR11 o S, donde R11 representa hidrogeno, alquilo C1-3 o ciclopropilo, R3 representa pirid-2-ilo, pirimid-2-ilo, 2-aminopirimid-4-ilo, 2-(mono-(alquil C1-4)-amino)pirimid-4-ilo, 2-(mono-cicloalquilamino C3-4)pirimid-4-ilo, piridazin-3(2H)-on-6-ilo; 1,3-oxazol-2-ilo, 1,3-oxazol-4-ilo, 1,2,4-oxadiazol-3-ilo, 1,2,3-oxadiazol-4-ilo, 1,3-tiazol-2-ilo, 1,3-tiazol-4-ilo, 1H-1,2,4-triazol-5-ilo, 2,4-dihidro-3H-1,2,4-triazol-3-on-5-ilo o 1,2-pirazol-5-ilo, donde pirid-2-ilo, pirimid-2-ilo, 1,3-oxazol-2-ilo, 1,3-oxazol-4-ilo, 1,3-tiazol-2-ilo y 1,3-tiazol-4-ilo están sustituidos con 1 o 2 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, nitro, amino, trifluorometilo, trifluorometoxi, aminocarbonilo, trifluorometilcarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, cicloalquilamino C3-4, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y ciclo alquilcarbonilo C3-6, donde alquilo, alcoxi, alquilamino, alquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo y cicloalquilcarbonilo pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por halogeno, ciano, hidroxilo, amino, trifluorometilo y cicloalquilo C3-5, y donde 2-aminopirimid-4-ilo, 2-(mono-(alquil C1-4)-amino)pirimid-4-ilo, 2-(mono-C3-4-cicloalquilamino)pirinlid-4-ilo, piridazin-3(2H)-on-6-ilo, 1,2,4-oxadiazol-3-ilo, 1,2,3-oxadiazol-4-ilo, 1H-1,2,4-triazol-5-ilo, 2,4-dihidro-3H-1,2,4-triazol-3-on-5-ilo y 1,2-pirazol-5-ilo pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por halogeno, ciano, nitro, amino, trifluorometilo, trifluorometoxi, aminocarbonilo, trifluorometilcarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, cicloalquilamino C3-4, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y cicloalquilcarbonilo C3-6, R4 representa hidrogeno, alquilo C1-3 o ciclopropilo, R5 representa hidrogeno o alquilo C1-3, R6 representa hidrogeno, alquilo C1-3 o ciclopropilo, R7 representa hidrogeno o alquilo C1-3, R8 representa hidrogeno, alquilo C1-3 o ciclopropilo, R9 representa hidrogeno o alquilo C1-3, R2 representa arilo C5-10 o heteroarilo de 5 a 10 miembros, donde arilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por hidroxilo, hidroximetilo, amino, halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alcoxi C1-4)metilo, (alquil C1-4)amino, (alquil C1-4)-aminometilo, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino, (alquil C1-4)sulfonilo, (alquil C1-4)sulfonilamino, (alquil C1-4)-aminosulfonilo, fenilo, benciloxi, heterociclilo de 5 o 6 miembros, heterociclilcarbonilo de 5 o 6 miembros, heterociclilmetilo de 5 o 6 miembros y heteroarilo de 5 o 6 miembros, donde fenilo, benciloxi, heterociclilo, heterociclilcarbonilo, heterociclilmetilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, o dos de los sustituyentes en arilo junto con los átomos de carbono a los que están unidos forman un 1,3-dioxolano o 1,4-dioxano; o una de sus sales, sus solvatos o los solvatos de sus sales.Claim 1: Compound of the formula (1) wherein u represents N, V represents CR12, w represents N, A represents CR15; ou represents N, v represents N, w represents CR16, A represents N, where R12 represents hydrogen, hydroxy, amino, hydroxycarbonyl, aminocarbonyl, trifluoromethyl, trifluoromethoxy, cyano, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl ) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl, (C1-4 alkyl) carbonylamino, C1-4 alkyl sulfonylamino, 5- or 6-membered heterocyclylcarbonyl, - CH2R13 or -CH2CH2R14, where heterocyclylcarbonyl is substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (alkyl C1-4) carbonyl, (C1-4 alkoxy) -carbonyl and (C1-4 alkyl) aminocarbonyl, and wherein alkoxy, alkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, alkylcarbonylamino and alkylsulfonylamino may be substituted with a substituent, the substituent being selected from the group consisting of hydroxyl, amino, hydroxycarb onyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl, C1-4 alkylcarbonylamino, 5- or 6-membered heterocyclyl and phenyl, where Phenyl may be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, aminocarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, ( C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, and where heterocyclyl can be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) -carbonyl and (C1-4 alkyl) aminocarbonyl , and where R13 represents hydroxyl, amino, cyano, hydroxycarbonyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (alkyl C1-4) aminocarbonyl, (C1-4 alkyl) carbonylamino or 5- or 6-membered heterocyclyl, wherein alkoxy, alkylamino, alkoxycarbonyl, alkylaminocarbonyl and alkylcarbonylamino may be substituted with a substituent, the substituent being selected from the group consisting of hydroxyl, amino, hydroxycarbonyl , aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, and where heterocyclyl can be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) - carbonyl and (C1-4 alkyl) aminocarbonyl, and where R14 represents hydroxyl, amino, cyano, hydroxycarbonyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl ) aminocarbonyl, (C 1-4 alkyl) carbonylamino or 5- or 6-membered heterocyclyl, where alkoxy, alkylamin or, alkoxycarbonyl, alkylaminocarbonyl and alkylcarbonylamino may be substituted with a substituent, the substituent being selected from the group consisting of hydroxyl, amino, hydroxycarbonyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, and where heterocyclyl can be substituted with 1 to 2 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1 alkoxy -4, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) -carbonyl and (C1-4 alkyl) aminocarbonyl, R15 represents hydrogen, halogen, cyano, trifluoromethyl, C1-3 alkyl , methoxy, methylthio or cyclopropyl, R16 represents hydrogen or methyl; represents a remainder of the group of formulas (2) in which * is the point of attachment to the heterocycle, n represents the number 0 or 1; X represents NR10, S or O, where R10 represents hydrogen, C1-3 alkyl or cyclopropyl, Y represents NR11 or S, where R11 represents hydrogen, C1-3 alkyl or cyclopropyl, R3 represents pyrid-2-yl, pyrimid-2- ilo, 2-aminopyrimid-4-yl, 2- (mono- (C1-4 alkyl) -amino) pyrimid-4-yl, 2- (mono-C3-4 cycloalkylamino) pyrimid-4-yl, pyridazin-3 ( 2H) -on-6-yl; 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,2,4-oxadiazol-3-yl, 1,2,3-oxadiazol-4-yl, 1,3-thiazole- 2-yl, 1,3-thiazol-4-yl, 1H-1,2,4-triazol-5-yl, 2,4-dihydro-3H-1,2,4-triazol-3-on-5- yl or 1,2-pyrazol-5-yl, where pyrid-2-yl, pyrimid-2-yl, 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,3-thiazole -2-yl and 1,3-thiazol-4-yl are substituted with 1 or 2 substituents, the substituents being selected independently from each other from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, alkyl C1-4, C1-4 alkoxy, (C1-4 alkyl) amino, C3-4 cycloalkylamino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and C3- alkylcarbonyl cycle 6, where alkyl, alkoxy, alkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl and cycloalkylcarbonyl may be substituted with a substituent, the substituent being selected from the group consisting of halogen, cyano, hydroxyl, amino, trifluoromethyl and c C3-5 icloalkyl, and where 2-aminopyrimid-4-yl, 2- (mono- (C1-4 alkyl) -amino) pyrimid-4-yl, 2- (mono-C3-4-cycloalkylamino) pyrinlid-4- ilo, pyridazin-3 (2H) -on-6-yl, 1,2,4-oxadiazol-3-yl, 1,2,3-oxadiazol-4-yl, 1H-1,2,4-triazol-5 -yl, 2,4-dihydro-3H-1,2,4-triazol-3-on-5-yl and 1,2-pyrazol-5-yl may be substituted with a substituent, the substituent being selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, C3-4 cycloalkylamino, (C1-4 alkoxy) carbonyl, (C1 alkyl -4) aminocarbonyl and C3-6 cycloalkylcarbonyl, R4 represents hydrogen, C1-3 alkyl or cyclopropyl, R5 represents hydrogen or C1-3 alkyl, R6 represents hydrogen, C1-3 alkyl or cyclopropyl, R7 represents hydrogen or C1-3 alkyl, R8 represents hydrogen, C1-3 alkyl or cyclopropyl, R9 represents hydrogen or C1-3 alkyl, R2 represents C5-10 aryl or 5-10 membered heteroaryl, where of aryl and heteroaryl may be substituted with 1 to 3 substituents, the substituents being selected independently from each other from the group consisting of hydroxy, hydroxymethyl, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, aminocarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkoxy) methyl, (C1-4 alkyl) amino, (C1-4 alkyl) -aminomethyl, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl, ( C1-4 alkyl) carbonylamino, (C1-4 alkyl) sulfonyl, (C1-4 alkyl) sulfonylamino, (C1-4 alkyl) -aminosulfonyl, phenyl, benzyloxy, 5- or 6-membered heterocyclyl, 5- or 6-membered heterocyclylcarbonyl, 5 or 6-membered heterocyclylmethyl and 5 or 6-membered heteroaryl, where phenyl, benzyloxy, heterocyclyl, heterocyclylcarbonyl, heterocyclylmethyl and heteroaryl may be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, a minocarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, or two of the aryl substituents together with the carbon atoms to which they are attached form a 1,3-dioxolane or 1,4-dioxane; or one of its salts, its solvates or the solvates of its salts.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007060172A DE102007060172A1 (en) | 2007-12-13 | 2007-12-13 | New nitrogen substituted heterocyclic compounds are glycogen synthase kinase 3-beta inhibitors useful e.g. to treat and/or prevent hematological disease, preferably leukopenia, and for ex-vivo increase of adult hematopoietic stem cells |
DE200810035209 DE102008035209A1 (en) | 2008-07-29 | 2008-07-29 | New nitrogen substituted heterocyclic compounds are glycogen synthase kinase 3-beta inhibitors useful e.g. to treat and/or prevent hematological disease, preferably leukopenia, and for ex-vivo increase of adult hematopoietic stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069636A1 true AR069636A1 (en) | 2010-02-10 |
Family
ID=40578190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105333A AR069636A1 (en) | 2007-12-13 | 2008-12-09 | TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090258877A1 (en) |
EP (1) | EP2229392A1 (en) |
JP (1) | JP2011506364A (en) |
AR (1) | AR069636A1 (en) |
CA (1) | CA2708783A1 (en) |
CL (1) | CL2008003602A1 (en) |
PA (1) | PA8806501A1 (en) |
PE (1) | PE20091074A1 (en) |
TW (1) | TW200938546A (en) |
UY (1) | UY31508A1 (en) |
WO (1) | WO2009074259A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6726923B2 (en) | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
KR20210049090A (en) | 2018-07-05 | 2021-05-04 | 인사이트 코포레이션 | Pyrazine derivatives fused as A2A/A2B inhibitors |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2198867A1 (en) * | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
KR20050057520A (en) * | 2002-09-23 | 2005-06-16 | 쉐링 코포레이션 | Imidazopyrazines as cyclin dependent kinase inhibitors |
DE602004008098T8 (en) * | 2003-10-10 | 2008-04-17 | Pfizer Products Inc., Groton | SUBSTITUTED 2H- [1,2,4] TRIAZOLO [4,3-A] PYRAZINES AS GSK-3 INHIBITORS |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
-
2008
- 2008-12-02 PE PE2008002006A patent/PE20091074A1/en not_active Application Discontinuation
- 2008-12-03 CL CL2008003602A patent/CL2008003602A1/en unknown
- 2008-12-03 UY UY31508A patent/UY31508A1/en not_active Application Discontinuation
- 2008-12-03 PA PA20088806501A patent/PA8806501A1/en unknown
- 2008-12-04 CA CA2708783A patent/CA2708783A1/en not_active Abandoned
- 2008-12-04 JP JP2010537294A patent/JP2011506364A/en active Pending
- 2008-12-04 WO PCT/EP2008/010279 patent/WO2009074259A1/en active Application Filing
- 2008-12-04 EP EP08858450A patent/EP2229392A1/en not_active Withdrawn
- 2008-12-09 AR ARP080105333A patent/AR069636A1/en unknown
- 2008-12-12 US US12/334,131 patent/US20090258877A1/en not_active Abandoned
- 2008-12-12 TW TW097148327A patent/TW200938546A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2708783A1 (en) | 2009-06-18 |
JP2011506364A (en) | 2011-03-03 |
US20090258877A1 (en) | 2009-10-15 |
CL2008003602A1 (en) | 2009-10-09 |
PE20091074A1 (en) | 2009-07-26 |
UY31508A1 (en) | 2009-08-03 |
EP2229392A1 (en) | 2010-09-22 |
TW200938546A (en) | 2009-09-16 |
PA8806501A1 (en) | 2009-08-26 |
WO2009074259A1 (en) | 2009-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069636A1 (en) | TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS. | |
AR050364A1 (en) | DERIVATIVES OF SULFONAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
AR078168A1 (en) | DERIVATIVES OF PIPERIDINS AND PIPERAZINS, PROCESSES TO PREPARE THEM AND THEIR USES AS MODULATORS OF GPR119 | |
AR065719A1 (en) | IMIDAZO AND TRIAZOLOPIRIMIDINAS, A PROCEDURE FOR ITS PREPARATION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HEMATOLOGICAL DISORDERS. | |
AR047538A1 (en) | PIRIDAZINONAS AS ANTAGONISTS OF THE INTEGRINES ALFA4 | |
AR062125A1 (en) | COMPOUNDS THAT MODULATE THE CB2 RECEIVER AND ITS USE AS MEDICATIONS | |
AR045747A1 (en) | DERIVATIVES OF 2,4 DI (IET) -ARILAMINO-PYRIMIDINE AS ZAP-70 INHIBITORS | |
AR073369A1 (en) | DERIVATIVES OF 2-CARBOXAMIDA-CICLOAMINO-UREA AS PI-3 INHIBITORS | |
AR069417A1 (en) | PIPERIDINAS HETEROARIL - SUBSTITUTED | |
AR048495A1 (en) | BENZOIL AMINO HETEROCICLICOS, USEFUL FOR THE TREATMENT OF GLK INTERMEDIATE DISEASES | |
AR050540A1 (en) | DERIVATIVES OF TRICICLIC ADAMANTILAMIDE AS INHIBITORS OF DEHYDROGENASE 11- BETA HYDROXYSTEROID | |
PE20091429A1 (en) | 4- (4-CYANE-2-THIOARIL) DIHYDROPYRIMIDINONES AS INHIBITORS OF HUMAN NEUTROPHYL ELASTASE (HNE) | |
CO6140033A2 (en) | AMINO-IMIDAZOLES AND ITS USE AS A MEDICINAL PRODUCT TO TREAT COOGNOTIVE DISABILITY ALZHEIMER NEURODEGENERATION AND DEMENTIA DISEASE | |
AR076908A1 (en) | ARIL-PYRIDINS AS INHIBITORS OF SINTASA DE ALDOSTERONA | |
RU2009118602A (en) | DERIVATIVE INDOLA | |
AR067327A1 (en) | PIPERIDINE / PIPERAZINE DERIVATIVES | |
CO6300864A2 (en) | POLISUSTITUTED DERIVATIVES OF 6-HETEROARIL-IMIDAZO [1,2-A] PIRIDINES ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
CO5640135A2 (en) | DERIVATIVES OF 4- (4- (HETEROCICLILALCOXI) -1- (HETEROCICLIL-CARBONIL) PIPERIDINE AND RELATED COMPOUNDS AS H3 HISTAMINE ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER | |
CO6251263A2 (en) | DERIVATIVES OF BENCIMIDAZOL AND INDOL SUBJECTED BY OXADIAZOL AND OXAZOL AS INHIBITORS OF DGAT1 | |
AR075868A1 (en) | 2-ACETAMIDO-5-ARIL-1,2,4-SUBSTITUTED TRIAZOLONS AND ITS USE | |
AR050281A1 (en) | DERIVATIVES OF INDOL, INDAZOL AND INDAZOLINA. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS | |
AR048004A1 (en) | NEW CUATERNIZED QUINUCLIDINE ESTERS | |
AR059493A1 (en) | ERK INHIBITING COMPOUNDS | |
AR041672A1 (en) | BICYCLE COMPOUND OF BENZAMIDA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE IT | |
AR058703A1 (en) | THYROSINKINASE INHIBITING TRIAZOLOPIRIDAZINS, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THERAPEUTIC AND USES IN THE TREATMENT OF CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |